How McFarlane was paid
$3.8M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Stock | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|---|
| Neil F. McFarlanePresident, Chief Executive Officer and Director | $729,167 | — | $874,125 | $1,748,250 | $418,950 | $11,550 | $3,782,042 |
| Rahsaan W. ThompsonChief Legal Officer, Secretary and Compliance Officer | $466,667 | $50,000 | $272,680 | $545,360 | $178,600 | $58,067 | $1,571,374 |
| R. LaDuane CliftonFormer Chief Financial Officer and Treasurer | $477,307 | — | $1,260,373 | $1,117,274 | — | $966,970 | $3,821,924 |
What changed and why
- $3.8MNeil F. McFarlane received total compensation of $3,782,042 in 2025, a decrease from $5,355,059 in 2024.
- $106.5MThe company generated $106.5 million in net revenue for the full year 2025.
- $150MZevra sold its Rare Pediatric Disease Priority Review Voucher for $150 million in 2025.
- R. LaDuane Clifton resigned as Chief Financial Officer and Treasurer effective December 31, 2025.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.